Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis

Purpose: The purpose of this study was to evaluate the efficacy and toxicity of a novel lanthanum compound, La(XT), in an ovariectomized (OVX) rat model of osteoporosis. Methods: Twenty-four ovariectomized female Sprague Dawley rats were divided into 3 groups receiving a research diet with/without t...

Full description

Bibliographic Details
Main Authors: Yunyun Di, Ellen K. Wasan, Jacqueline Cawthray, Jaweria Syeda, Munawar Ali, David M.L. Cooper, Ahmad Al-Dissi, Nima Ashjaee, Wubin Cheng, James Johnston, David M. Weekes, Thomas I. Kostelnik, Chris Orvig, Kishor M. Wasan
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Bone Reports
Subjects:
OVX
Online Access:http://www.sciencedirect.com/science/article/pii/S2352187221000085
id doaj-fac871169e1141f6bfd54cfe9719e150
record_format Article
spelling doaj-fac871169e1141f6bfd54cfe9719e1502021-06-03T04:57:20ZengElsevierBone Reports2352-18722021-06-0114100753Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosisYunyun Di0Ellen K. Wasan1Jacqueline Cawthray2Jaweria Syeda3Munawar Ali4David M.L. Cooper5Ahmad Al-Dissi6Nima Ashjaee7Wubin Cheng8James Johnston9David M. Weekes10Thomas I. Kostelnik11Chris Orvig12Kishor M. Wasan13College of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N 2Z4, CanadaCollege of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N 2Z4, CanadaCollege of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N 2Z4, CanadaCollege of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N 2Z4, CanadaCollege of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N 2Z4, CanadaDepartment of Anatomy Physiology and Pharmacology, College of Medicine, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK S7N 5E5, CanadaWestern College of Veterinary Medicine, University of Saskatchewan, 52 Campus Drive, Saskatoon, SK S7N 5B4, CanadaCollege of Engineering, University of Saskatchewan, 57 Campus Drive, Saskatoon, SK S7N 5A9, CanadaCollege of Engineering, University of Saskatchewan, 57 Campus Drive, Saskatoon, SK S7N 5A9, CanadaCollege of Engineering, University of Saskatchewan, 57 Campus Drive, Saskatoon, SK S7N 5A9, CanadaMedicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, CanadaMedicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, CanadaMedicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, BC V6T 1Z1, CanadaCollege of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Place, Saskatoon, SK S7N 2Z4, Canada; Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Corresponding author at: Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Canada.Purpose: The purpose of this study was to evaluate the efficacy and toxicity of a novel lanthanum compound, La(XT), in an ovariectomized (OVX) rat model of osteoporosis. Methods: Twenty-four ovariectomized female Sprague Dawley rats were divided into 3 groups receiving a research diet with/without treatment compounds (alendronate: 3 mg/kg; La(XT) 100 mg/kg) for three months. At the time of sacrifice, the kidney, liver, brain, lung and spleen were collected for histological examination. The trabecular bone structure of the tibiae was evaluated using micro-CT and a three-point metaphyseal mechanical test was used to evaluate bone failure load and stiffness. Results: No significant differences were noted in plasma levels of calcium, phosphorus, creatinine, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) between the La(XT) treatment compared to the non-treated OVX group. Alendronate-treated animals (positive control) showed higher BV/TV, Tb.N and lower Tb.Th and Tb.Sp when compared to the non-treated OVX group. Mechanical analysis indicated that stiffness was higher in the alendronate (32.88%, p = 0.04) when compared to the non-treated OVX group. Failure load did not differ among the groups. Conclusions: No kidney or liver toxicities of La(XT) treatments were found during the three-month study. The absence of liver and kidney toxicity with drug treatment for 3 months, as well as the increased trabecular bone stiffness are encouraging for the pursuit of further studies with La(XT) for a longer duration of time.http://www.sciencedirect.com/science/article/pii/S2352187221000085OsteoporosisLanthanumLa(XT)OVXToxicity
collection DOAJ
language English
format Article
sources DOAJ
author Yunyun Di
Ellen K. Wasan
Jacqueline Cawthray
Jaweria Syeda
Munawar Ali
David M.L. Cooper
Ahmad Al-Dissi
Nima Ashjaee
Wubin Cheng
James Johnston
David M. Weekes
Thomas I. Kostelnik
Chris Orvig
Kishor M. Wasan
spellingShingle Yunyun Di
Ellen K. Wasan
Jacqueline Cawthray
Jaweria Syeda
Munawar Ali
David M.L. Cooper
Ahmad Al-Dissi
Nima Ashjaee
Wubin Cheng
James Johnston
David M. Weekes
Thomas I. Kostelnik
Chris Orvig
Kishor M. Wasan
Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis
Bone Reports
Osteoporosis
Lanthanum
La(XT)
OVX
Toxicity
author_facet Yunyun Di
Ellen K. Wasan
Jacqueline Cawthray
Jaweria Syeda
Munawar Ali
David M.L. Cooper
Ahmad Al-Dissi
Nima Ashjaee
Wubin Cheng
James Johnston
David M. Weekes
Thomas I. Kostelnik
Chris Orvig
Kishor M. Wasan
author_sort Yunyun Di
title Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis
title_short Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis
title_full Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis
title_fullStr Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis
title_full_unstemmed Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis
title_sort evaluation of la(xt), a novel lanthanide compound, in an ovx rat model of osteoporosis
publisher Elsevier
series Bone Reports
issn 2352-1872
publishDate 2021-06-01
description Purpose: The purpose of this study was to evaluate the efficacy and toxicity of a novel lanthanum compound, La(XT), in an ovariectomized (OVX) rat model of osteoporosis. Methods: Twenty-four ovariectomized female Sprague Dawley rats were divided into 3 groups receiving a research diet with/without treatment compounds (alendronate: 3 mg/kg; La(XT) 100 mg/kg) for three months. At the time of sacrifice, the kidney, liver, brain, lung and spleen were collected for histological examination. The trabecular bone structure of the tibiae was evaluated using micro-CT and a three-point metaphyseal mechanical test was used to evaluate bone failure load and stiffness. Results: No significant differences were noted in plasma levels of calcium, phosphorus, creatinine, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) between the La(XT) treatment compared to the non-treated OVX group. Alendronate-treated animals (positive control) showed higher BV/TV, Tb.N and lower Tb.Th and Tb.Sp when compared to the non-treated OVX group. Mechanical analysis indicated that stiffness was higher in the alendronate (32.88%, p = 0.04) when compared to the non-treated OVX group. Failure load did not differ among the groups. Conclusions: No kidney or liver toxicities of La(XT) treatments were found during the three-month study. The absence of liver and kidney toxicity with drug treatment for 3 months, as well as the increased trabecular bone stiffness are encouraging for the pursuit of further studies with La(XT) for a longer duration of time.
topic Osteoporosis
Lanthanum
La(XT)
OVX
Toxicity
url http://www.sciencedirect.com/science/article/pii/S2352187221000085
work_keys_str_mv AT yunyundi evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis
AT ellenkwasan evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis
AT jacquelinecawthray evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis
AT jaweriasyeda evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis
AT munawarali evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis
AT davidmlcooper evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis
AT ahmadaldissi evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis
AT nimaashjaee evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis
AT wubincheng evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis
AT jamesjohnston evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis
AT davidmweekes evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis
AT thomasikostelnik evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis
AT chrisorvig evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis
AT kishormwasan evaluationoflaxtanovellanthanidecompoundinanovxratmodelofosteoporosis
_version_ 1721399778511683584